End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
231.5 MXN | -3.73% |
|
-3.73% | -3.42% |
06-25 | US CDC alerts healthcare providers of increase in dengue cases | RE |
06-25 | Takeda's Cancer Drug Gets European Commission Approval | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.96 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.42% | 40.23B | - | ||
+55.19% | 801B | C+ | ||
+47.26% | 631B | B | ||
-6.09% | 359B | C+ | ||
+21.92% | 337B | B- | ||
+18.40% | 245B | B+ | ||
+3.64% | 231B | A+ | ||
+12.98% | 219B | B- | ||
+10.86% | 171B | C+ | ||
-2.78% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4502 Stock
- TAK N Stock
- Ratings Takeda Pharmaceutical Company Limited